In our current environment, the Diagnostics industry is faced with increasing challenges that have an impact on how we operate (business models) and how we generate profit. Western European markets have seen caps on test volumes or decreases in reimbursement tariffs; Emerging Markets have partially enjoyed an increase in wealth but struggled in defining sustainable funding systems, many of which remain based on out-of-pocket payments.



